Surgery Partners Inc. (SGRY) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Surgery Partners Inc. (SGRY) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How SGRY Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $4.00B | 0% | 9.7% | -$77.9M | $195.6M | 9.1% |
| FY 2024 | $4.00B | 0% | 8.7% | -$168.1M | $209.7M | 8.2% |
| FY 2023 | $4.00B | 0% | 8.2% | -$11.9M | $293.8M | 25.7% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring SGRY)
- ✓Live walkthrough of SGRY's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
SGRY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SGRY today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SGRY. Explore sector supply chains on /butterfly.
SGRY Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Surgery Partners Inc. (SGRY)?
In FY 2025 (10-K), SGRY converted $4.0B of revenue into a 0% gross margin, 0% operating margin, and $195.6M in free cash flow (4.9% FCF margin).